Article Details

PureTech Advances Wholly Owned Candidate LYT-200 into Phase 1 Trial for Potential Treatment ...

Retrieved on: 2020-12-11 14:48:45

Tags for this article:

Click the tags to see associated articles and topics

PureTech Advances Wholly Owned Candidate LYT-200 into Phase 1 Trial for Potential Treatment .... View article details on hiswai:

Excerpt

LYT-200 is a <b>monoclonal antibody</b> designed to block a foundational immunosuppressive protein, galectin-9, which is associated with poor survival ...

Article found on: pipelinereview.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo